Ocular Nanoparticle Formulation for Sustained Mucosal Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional topical drug administration methods for the eye, such as eye drops, suffer from poor ocular bioavailability and require frequent applications due to static and dynamic barriers, leading to potential toxicity and noncompliance issues.
Innovation Solution
Development of a pharmaceutical formulation comprising nanoparticles with amphiphilic block copolymers and an anionic polymer matrix for sustained drug release, which includes surface targeting moieties to enhance penetration and retention on the eye surface.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional eye drop formulations are used, then frequent application is required to maintain therapeutic dose, but this leads to toxic side effects and cellular damages at the corneal surface
Solution Approach 1:
The drug is segmented into nanoparticle carriers (amphiphilic block copolymer micelles) that can deliver the drug in controlled amounts directly to the target site, reducing the need for frequent high-concentration applications that cause toxicity
Solution Approach 2:
The amphiphilic block copolymer acts as an intermediary carrier that facilitates drug delivery through the corneal barriers, enabling sustained release at therapeutic concentrations without the peak concentrations that cause cellular damage
2Reliability
If conventional eye drop formulations are used, then frequent instillations are needed to maintain therapeutic dose, but this results in noncompliance due to high application frequency
Solution Approach 1:
The nanoparticle formulation provides continuous sustained drug release over extended periods (maintaining therapeutic levels for days), eliminating the need for frequent discrete applications and improving patient compliance
Solution Approach 2:
The formulation dynamically adjusts drug release rates based on the ocular environment, providing sustained therapeutic levels without requiring frequent patient intervention
3Ease of operation
If conventional eye drop formulations are used, then the drug can be easily administered, but poor ocular bioavailability results due to static and dynamic barriers
Solution Approach 1:
The invention changes the physical and chemical parameters of the drug delivery system by using nanoparticle carriers with specific size ranges (20-200 nm) and surface properties that can penetrate corneal barriers while maintaining ease of topical administration
Solution Approach 2:
The formulation uses composite amphiphilic block copolymers combining hydrophilic and hydrophobic segments that can interact with both aqueous tear fluid and lipid-rich corneal barriers, enhancing penetration while maintaining simple drop administration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves increased therapeutic efficacy by reducing application frequency from multiple times a day to once every 2-3 days, while maintaining effective drug delivery and minimizing surface toxicity.
Implementation Method 1
penetration through the mucus layer via active transport mechanisms
Implementation Method 2
The particles are further modified with surface targeting moieties that interact with epithelial mucin through molecular recognition
Data Source
Figure 1~2B
Figure 3A~3C
Figure 4A~4B
AI summary
Disclosed herein are polymers, nanoparticles, and pharmaceutical compositions and formulations that are useful for topical delivery of therapeutic agents to an eye of an subject in need thereof.